Related Experiment Videos
Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor
Krysten A Modrzejewski1, Ronald A Herman
1Iowa Drug Information Service, University of Iowa Hospitals and Clinics, 100 Oakdale Campus, Iowa City, IA 52242-5000, USA.
The Annals of Pharmacotherapy
|May 4, 2004
Summary
Emtricitabine is a safe and effective nucleoside reverse transcriptase inhibitor (NRTI) for treating HIV-1 infection in adults. It offers potential advantages over other NRTIs, including improved adherence and reduced drug resistance.
Area of Science:
- Pharmacology
- Virology
- Pharmacokinetics
- Safety and Efficacy
Background:
- Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) used in HIV-1 treatment.
- The study reviews existing data on emtricitabine's properties and performance.
Purpose of the Study:
- To comprehensively review the pharmacology, virology, pharmacokinetics, safety, and efficacy of emtricitabine.
- To evaluate emtricitabine as a treatment option for HIV-1 infection.
Main Methods:
- Literature search of MEDLINE and Iowa Drug Information Service (1966-June 2003).
- Inclusion of published and unpublished abstracts, posters, and oral presentations from scientific conferences.
- Preference for published controlled trials evaluating emtricitabine's pharmacology, virology, effectiveness, safety, or pharmacokinetics.
Main Results:
- Emtricitabine is an NRTI for HIV-1 treatment.
- Once-daily dosing may improve adherence in multidrug HIV therapy.
- Emtricitabine demonstrated equivalent or superior outcomes compared to lamivudine and stavudine.
Conclusions:
- Emtricitabine is a safe and effective component of adult HIV-1 multidrug regimens.
- Its extended intracellular half-life may make it a preferred option for once-daily therapy over lamivudine.
- Emtricitabine may offer a reduced potential for drug resistance compared to lamivudine and stavudine.